Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.

Area of Science:

• Oncology
• Pharmacology
• Clinical Research

Background:

• Lurbinectedin shows promise for relapsed small cell lung cancer (SCLC).
• Limited real-world data exist on its use in SCLC.
• This study addresses the need for real-world evidence on lurbinectedin's safety and efficacy.

Purpose of the Study:

• To evaluate the safety and efficacy of lurbinectedin in a real-world setting.
• To assess lurbinectedin as a second-line and later-line treatment for SCLC patients.
• To compare real-world findings with existing clinical trial data.

Main Methods:

• Retrospective analysis of 90 SCLC patients treated with lurbinectedin (June 2020 - June 2022).
• Patients included those receiving lurbinectedin as second-line (n=50) or third-line or later (n=14) therapy.
• Primary outcomes: overall survival (OS), progression-free survival (PFS), and adverse events.

Main Results:

• Lurbinectedin was well-tolerated with manageable adverse events (neutropenia, anemia, fatigue).
• Median OS: 5.1 months (second-line) and 5.6 months (third-line+).
• Median PFS: 2.1 months (second-line) and 3.4 months (third-line+). No treatment-related deaths.

Conclusions:

• Real-world data confirm lurbinectedin's modest efficacy and safety profile in relapsed SCLC.
• Outcomes for relapsed SCLC remain suboptimal.
• Factors like shorter chemotherapy-free intervals and CNS metastases impact patient outcomes.